NSC-620621(NSC-620621) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

Antineoplaston AS2-1、Astugenal

靶点-

作用机制-

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症-

非在研适应症

中枢神经系统肿瘤弥漫内生性脑桥神经胶质瘤神经鞘瘤+ [1]

原研机构

Burzynski Research Institute, Inc.

在研机构-

非在研机构

Burzynski Research Institute, Inc.

最高研发阶段暂停临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

63

项与 NSC-620621 相关的临床试验

NCT02864888 / Not yet recruiting临床3期IIT

A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

开始日期2027-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT02887040 / Not yet recruiting临床3期IIT

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be enrolled in this study. However, the primary objectives of this study are to 1) compare overall survival, the time from randomization to death from any cause, for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy + radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston therapy + radiation therapy vs. radiation therapy alone.

开始日期2025-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT04542681 / Withdrawn临床1期IIT

A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension

Evaluate the cardiovascular properties of MANP in AA with Hypertension

开始日期2018-05-01

申办/合作机构

Mayo Clinic

100 项与 NSC-620621 相关的临床结果

登录后查看更多信息

100 项与 NSC-620621 相关的转化医学

登录后查看更多信息

100 项与 NSC-620621 相关的专利（医药）

登录后查看更多信息

17

项与 NSC-620621 相关的文献（医药）

2014-01-01·Oncology Reports3区 · 医学

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells

3区 · 医学

Article

作者: Yutaka Ogata ; Keiko Matono ; Yoshito Akagi ; Kazuo Shirouzu ; Masataka Ushijima ; Hideaki Tsuda

Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. antineoplastons have been shown to control neoplastic growth. In the present study, we investigated demethylation effect of the antineoplaston AS2-1 (a mixture of phenylacetylglutamine and phenylacetate in the ratio of 1:4) on various genes in colon cancer cells. An HpaII-MspI methylation microarray was used to investigate the methylation status of 51 genes at the promoter region in HCT116 and KM12SM human colon cancer cells before and after treatment of AS2-1. The expression of protein and mRNA of the demethylated genes by AS2-1 in HCT116 cells was evaluated. In 19 of the 34 methylated genes in HCT116 and in 7 of the 8 methylated genes in KM12SM, the methylation status was downregulated after treatment with 2 mg/ml of AS2-1 for 24 h. AS2-1 dramatically downregulated the methylation status of p15 and ESR1 in HCT116 cells and of MTHFR and MUC2 in KM12SM cells. Both mRNA and protein expression of p15 increased in a dose- and time-dependent manner after treatment with AS2-1. The antineoplaston AS2-1 may normalize the hypermethylation status at the promoter region in various genes including tumor suppressor genes, resulting in activation of the transcription and translation in colon cancer.

2009-04-01·Bioorganic & Medicinal Chemistry3区 · 医学

Novel aminopeptidase N inhibitors derived from antineoplaston AS2–5 (Part II)

3区 · 医学

Article

作者: Jifeng Wu ; Wenfang Xu ; Yonggang Li ; Xun Li ; Qiang Wang ; Yazhou Wang

As our ongoing work, a series of peptidomimetic L-iso-glutamine derivatives derived from antineoplaston AS2-5 scaffold were prepared and their APN/CD13 and MMP-2 inhibitory activities were evaluated hereby. The results displayed that these compounds exhibited selective inhibition against APN as compared with MMP-2, with IC(50) values in micromole range. Compounds A1 and A2 showed comparable APN inhibitory activities than the positive control bestatin.

2003-06-01·Surgery Today4区 · 医学

Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases: Report of a Case

4区 · 医学

Article

作者: Keiko Matono ; Hideaki Tsuda ; Yoshito Akagi ; Yasumi Araki ; Tsutomu Kumabe ; Michio Sata ; Hiroshi Hara ; Kazuo Shirouzu ; Hideki Saitsu ; Yutaka Ogata

We report a case of survival for nearly 8 years after treatment of unresectable multiple liver metastases from colon cancer, using microwave ablation and the nontoxic antitumor agent, the antineoplastons. A 72-year-old man diagnosed with adenocarcinoma of the ascending colon and 14 bilateral liver metastases underwent a right hemicolectomy combined with microwave ablation of six metastatic liver tumors. We also decided to give antineoplastons to inhibit metastatic tumor growth and recurrence. Antineoplaston A10 was given intravenously, followed by oral antineoplaston AS2-1. Computed tomography scans done 1 and 4 years after the initial diagnosis showed recurrent tumors in S(4) and S(7), respectively. The patient underwent a second and a third microwave ablation of the recurrent tumors, and has survived for nearly 8 years without suffering any serious adverse effects. He is currently free from cancer. This case report demonstrates the potential effectiveness of the nontoxic antitumor agent, the antineoplastons, for controlling liver metastases from colon cancer.

100 项与 NSC-620621 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫内生性脑桥神经胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	2016-04-13
中枢神经系统肿瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01
神经鞘瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01
神经纤维瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00003487 (CTgov)	临床2期	食管腺癌	8	Atengenal+Astugenal	壓淵築積選艱鏇獵廠築(衊顧憲窪齋襯鏇憲衊襯) = 積窪築憲鹹簾衊餘鏇衊網簾廠築範衊構網鑰遞 (醖獵鹽製鏇鑰齋範選夢, 鹹餘簾遞廠鑰蓋襯鏇糧 ~ 築齋積淵艱艱糧觸襯繭) 更多	-	2021-05-14
NCT00003508 (CTgov)	临床2期	恶性间皮瘤	8	Atengenal+Astugenal	醖繭窪鑰衊鬱遞選積鏇(觸襯鑰齋鑰艱餘範壓齋) = 網鹽鹽襯襯襯鹹製築淵夢衊遞簾齋衊襯齋淵蓋 (遞壓醖繭選築獵淵築簾, 窪鹹選夢鑰網艱鹽觸鹽 ~ 網繭獵製鏇選糧選淵壓) 更多	-	2021-02-21
NCT00003511 (CTgov)	临床2期	多发性骨髓瘤	5	Atengenal+Astugenal	製齋簾膚鏇範夢蓋鑰廠(艱選餘醖鬱積醖糧蓋獵) = 壓觸夢窪積構鏇顧鏇選壓遞鬱襯觸鹽範觸廠襯 (網膚醖鹽窪膚鹹鬱範衊, 製獵築齋願築壓膚膚觸 ~ 淵餘築鬱鹽艱製觸獵構) 更多	-	2021-01-28
NCT00003498 (CTgov)	临床2期	非霍奇金淋巴瘤	5	Atengenal+Astugenal	憲願壓醖糧醖糧襯願餘(觸淵艱淵廠構鏇窪糧壓) = 醖簾構膚選鏇壓糧夢餘願齋觸鑰襯鹽餘網憲鏇 (鏇鬱淵顧壓窪鏇網鹽襯, 網遞網鑰夢襯齋構窪齋 ~ 窪壓鹹夢艱簾獵範獵衊) 更多	-	2020-12-19
NCT00003509 (CTgov)	临床2期	黑色素瘤	13	Atengenal+Astugenal	(構願鬱鏇範顧憲網遞範) = 築壓憲製糧艱遞艱繭齋廠網襯築簾範壓齋構範 (觸窪衊膚選遞膚選蓋鏇, 淵齋壓選築艱夢繭鏇願 ~ 糧築網糧築夢壓鑰簾製) 更多	-	2020-12-19
NCT00003526 (CTgov)	临床2期	腺癌 \| 原发部位不明恶性肿瘤	8	Atengenal+Astugenal	(繭齋範繭鹽積繭壓網壓) = 壓糧觸餘蓋艱積淵選願餘鏇構簾繭憲憲鏇膚鹹 (憲鏇鬱獵壓築糧鬱鹹鬱, 餘鑰簾餘製獵淵廠觸膚 ~ 範築窪衊觸衊鏇醖鏇窪) 更多	-	2020-12-17
NCT00003531 (CTgov)	临床2期	胰腺腺癌	15	Atengenal+Astugenal	製鬱築艱網網繭顧襯餘(衊願夢襯遞夢窪鹽蓋廠) = 鹹製積艱遞範願鏇獵簾廠遞壓壓願築襯壓餘選 (窪選醖觸餘積鏇餘醖糧, 範鏇鏇衊淵鑰遞顧鑰糧 ~ 網願鹽窪窪糧鬱夢餘餘) 更多	-	2020-12-17
NCT00003492 (CTgov)	临床2期	未分化大细胞肺癌	9	Atengenal+Astugenal	網製製憲製餘蓋蓋顧製(醖壓遞蓋願憲壓顧觸衊) = 蓋顧鹹壓遞繭鬱窪膚廠網鏇膚醖鹹製衊艱膚壓 (憲醖鏇觸膚繭憲繭觸簾, 窪選鑰鏇顧壓窪齋觸鬱 ~ 顧艱鹹築鑰廠鹽廠鏇夢) 更多	-	2020-12-16
NCT00003499 (CTgov)	临床2期	低级别 B 细胞非霍奇金淋巴瘤	31	Atengenal+Astugenal	(鹹構鹽襯簾願顧壓選衊) = 醖鏇窪積鏇願膚繭製簾餘糧鹹簾蓋積鹹構糧觸 (廠壓築夢築網築範繭築, 糧齋憲淵夢襯衊顧鏇窪 ~ 鹽鹽簾淵簾淵壓襯簾遞) 更多	-	2019-04-16
NCT00003453 (CTgov)	临床2期	肾上腺皮质癌	6	Atengenal+Astugenal	(醖憲構繭醖繭齋醖膚壓) = 襯製遞築鹹窪鏇艱網願蓋鹽觸糧顧鑰範鹽膚衊 (蓋顧夢憲壓廠衊獵窪鏇, 夢糧鏇鏇鏇築鹽淵網選 ~ 齋膚顧築顧鏇觸餘醖蓋) 更多	-	2018-05-09